Martine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $331.32, for a total transaction of $1,192,752.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $43,071.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

United Therapeutics Stock Up 1.4 %

UTHR stock opened at $336.37 on Friday. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $343.98. The firm’s 50-day simple moving average is $301.73 and its 200 day simple moving average is $256.49. The stock has a market cap of $14.92 billion, a PE ratio of 15.90, a price-to-earnings-growth ratio of 1.47 and a beta of 0.55.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The firm had revenue of $677.70 million during the quarter, compared to analyst estimates of $620.31 million. During the same quarter in the prior year, the firm posted $4.86 EPS. United Therapeutics’s revenue was up 33.7% compared to the same quarter last year. As a group, sell-side analysts predict that United Therapeutics Co. will post 24.87 EPS for the current year.

Hedge Funds Weigh In On United Therapeutics

Large investors have recently made changes to their positions in the business. V Square Quantitative Management LLC bought a new position in shares of United Therapeutics during the 2nd quarter valued at about $30,000. Rise Advisors LLC bought a new position in shares of United Therapeutics during the 1st quarter valued at about $32,000. GAMMA Investing LLC bought a new position in shares of United Therapeutics during the 4th quarter valued at about $43,000. Benjamin F. Edwards & Company Inc. boosted its position in shares of United Therapeutics by 63.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 117 shares in the last quarter. Finally, 1620 Investment Advisors Inc. purchased a new stake in United Therapeutics during the second quarter valued at about $123,000. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

UTHR has been the subject of several analyst reports. HC Wainwright upped their target price on shares of United Therapeutics from $300.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday. The Goldman Sachs Group upped their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a report on Friday, May 3rd. Oppenheimer upped their price target on shares of United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a report on Thursday, May 2nd. Wells Fargo & Company upped their price target on shares of United Therapeutics from $325.00 to $350.00 and gave the company an “overweight” rating in a report on Wednesday, June 12th. Finally, TD Cowen upped their price target on shares of United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a report on Thursday, July 11th. Two equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $330.64.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.